Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Leerink Partners analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and raises the price target from $122 to $129.